Skip to main content
. 2023 Apr 12;18(4):e0282042. doi: 10.1371/journal.pone.0282042

Fig 1. Overview of the AI-DTI pipeline.

Fig 1

(A) A structure of AI-DTI. (B) Feature vector generation for activatory and inhibitory drug-target interactions (DTIs). For activatory DTIs, the feature vector was represented as a concatenation of the compound vector and aggregated gene overexpression signatures. For inhibitory DTIs, the feature vector was represented as a concatenation of the compound vector and aggregated gene knockdown signatures.